Blogs

FDA to Give Generics More Prominence: Rumors of Change

Not Pfizer? All the More Reason to Think Big about Securing the Supply Chain

FDA Warning Letter to GSK Worthing: Prudent or Picky?

Quality by Design: A Regulatory Initiative No More?

When Guidelines Need Guidance: ICH Releases “Points to Consider”